Keros Therapeutics Inc (KROS)

$46.44

+1.03

(+2.27%)

Market is closed - opens 7 PM, 24 Jun 2024

Insights on Keros Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 78.5% return, outperforming this stock by 66.5%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 247.7% return, outperforming this stock by 243.5%

Performance

  • $45.24
    $46.68
    $46.44
    downward going graph

    2.59%

    Downside

    Day's Volatility :3.09%

    Upside

    0.5%

    downward going graph
  • $27.02
    $73.00
    $46.44
    downward going graph

    41.82%

    Downside

    52 Weeks Volatility :62.99%

    Upside

    36.38%

    downward going graph

Returns

PeriodKeros Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-29.91%
0.9%
0.0%
6 Months
15.41%
8.7%
0.0%
1 Year
11.96%
11.2%
0.0%
3 Years
4.2%
17.9%
-23.2%

Highlights

Market Capitalization
1.6B
Book Value
$12.59
Earnings Per Share (EPS)
-5.15
Wall Street Target Price
90.63
Profit Margin
0.0%
Operating Margin TTM
-58413.26%
Return On Assets TTM
-25.79%
Return On Equity TTM
-39.63%
Revenue TTM
234.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
-87.3M
EBITDA
-178.6M
Diluted Eps TTM
-5.15
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-4.86
EPS Estimate Next Year
-5.16
EPS Estimate Current Quarter
-1.35
EPS Estimate Next Quarter
-1.34

Analyst Recommendation

Buy
    93%Buy
    6%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Keros Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
15
15
15
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 95.16%

Current $46.44
Target $90.63

Technicals Summary

Sell

Neutral

Buy

Keros Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Keros Therapeutics Inc
Keros Therapeutics Inc
-5.53%
15.41%
11.96%
4.2%
-9.79%
Moderna, Inc.
Moderna, Inc.
-18.66%
37.06%
12.57%
-37.09%
850.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
7.4%
23.97%
35.06%
98.78%
236.95%
Novo Nordisk A/s
Novo Nordisk A/s
4.71%
38.25%
78.49%
247.73%
453.56%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.97%
14.98%
35.07%
149.95%
158.93%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Keros Therapeutics Inc
Keros Therapeutics Inc
NA
NA
NA
-4.86
-0.4
-0.26
NA
12.59
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.7
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
30.93
30.93
1.46
44.13
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
49.78
49.78
2.36
3.47
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
30.61
30.61
0.53
17.09
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Keros Therapeutics Inc
Keros Therapeutics Inc
Buy
$1.6B
-9.79%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$51.5B
850.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$115.3B
236.95%
30.93
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$644.0B
453.56%
49.78
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$121.7B
158.93%
30.61
39.46%

Institutional Holdings

  • FMR Inc

    13.91%
  • BlackRock Inc

    6.00%
  • Alkeon Capital Management, LLC

    4.43%
  • State Street Corporation

    4.33%
  • Vanguard Group Inc

    4.28%
  • Darwin Global Management, Ltd.

    3.98%

Company Information

keros therapeutics, inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. the company's lead protein therapeutic product candidate is ker-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or mds, and in patients with myelofibrosis. it is also developing small molecule product candidate ker-047 that is being developed for the treatment of anemia, as well as for the treatment of fibrodysplasia ossificans progressiva, or fop, and is currently in a phase 1 clinical trial; and ker-012 being developed for the treatment of disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension, or pah. the company was founded i

Organization
Keros Therapeutics Inc
Employees
141
CEO
Dr. Jasbir S. Seehra Ph.D.
Industry
Commercial Services

FAQs